Sarepta's Gene Therapy: FDA Challenges and Market Withdrawal

Sarepta's Gene Therapy and FDA Request

• ⚠️ Sarepta's stock declined significantly after a third patient death linked to its gene therapy treatment, Elevidys.
• 💡 The FDA requested Sarepta voluntarily halt shipments of the gene therapy, but the company stated patient safety remains their top priority and they will continue shipping to ambulatory patients.
• 🔬 The FDA's request for a voluntary halt came two weeks after they were aware of a patient death in another trial, raising questions about the FDA's motivations.

Patient Population and Safety Profile

• 🎯 In non-ambulatory patients, Sarepta has paused shipments of the drug.
• ✅ However, the company continues to ship the drug to ambulatory patients, where there have been zero deaths reported so far.
• ⚠️ Acknowledged is the